Switch to:

Amplia Therapeutics Piotroski F-Score

: 3 (As of Today)
View and export this data going back to 2015. Start your Free Trial

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Amplia Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

OTCPK:INNMF' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 4
Current: 3

2
4

During the past 8 years, the highest Piotroski F-Score of Amplia Therapeutics was 4. The lowest was 2. And the median was 3.


Amplia Therapeutics Piotroski F-Score Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Amplia Therapeutics Annual Data
Jun13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only 2.00 3.00 4.00 2.00 3.00

Amplia Therapeutics Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 0.00 2.00 0.00 3.00

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Amplia Therapeutics Piotroski F-Score Distribution

* The bar in red indicates where Amplia Therapeutics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

This Year (Mar20) TTM:Last Year (Mar19) TTM:
Net Income was $-1.38 Mil.
Cash Flow from Operations was $-1.30 Mil.
Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Average Total Assets from the begining of this year (Mar19)
to the end of this year (Mar20) was (6.5092067988669 + 5.6691542288557) / 2 = $6.0891805138613 Mil.
Total Assets at the begining of this year (Mar19) was $6.51 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.73 Mil.
Total Current Liabilities was $0.32 Mil.
Net Income was $-1.32 Mil.

Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Average Total Assets from the begining of last year (Mar18)
to the end of last year (Mar19) was (2.0512024825446 + 6.5092067988669) / 2 = $4.2802046407057 Mil.
Total Assets at the begining of last year (Mar18) was $2.05 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.89 Mil.
Total Current Liabilities was $0.37 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Amplia Therapeutics's current Net Income (TTM) was -1.38. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Amplia Therapeutics's current Cash Flow from Operations (TTM) was -1.30. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar19)
=-1.3799751243781/6.5092067988669
=-0.21200358

ROA (Last Year)=Net Income/Total Assets (Mar18)
=-1.3243626062323/2.0512024825446
=-0.64565182

Amplia Therapeutics's return on assets of this year was -0.21200358. Amplia Therapeutics's return on assets of last year was -0.64565182. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Amplia Therapeutics's current Net Income (TTM) was -1.38. Amplia Therapeutics's current Cash Flow from Operations (TTM) was -1.30. ==> -1.30 > -1.38 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar19 to Mar20
=0/6.0891805138613
=0

Gearing (Last Year: Mar19)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar18 to Mar19
=0/4.2802046407057
=0

Amplia Therapeutics's gearing of this year was 0. Amplia Therapeutics's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar20)=Total Current Assets/Total Current Liabilities
=0.73258706467662/0.31778606965174
=2.30528376

Current Ratio (Last Year: Mar19)=Total Current Assets/Total Current Liabilities
=0.88668555240793/0.37322946175637
=2.37571157

Amplia Therapeutics's current ratio of this year was 2.30528376. Amplia Therapeutics's current ratio of last year was 2.37571157. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Amplia Therapeutics's number of shares in issue this year was 52.401. Amplia Therapeutics's number of shares in issue last year was 42.979. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Amplia Therapeutics's gross margin of this year was . Amplia Therapeutics's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar19)
=0/6.5092067988669
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar18)
=0/2.0512024825446
=0

Amplia Therapeutics's asset turnover of this year was 0. Amplia Therapeutics's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Amplia Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Amplia Therapeutics  (OTCPK:INNMF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Amplia Therapeutics Piotroski F-Score Related Terms


Amplia Therapeutics Piotroski F-Score Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)